Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
Go back to Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome| (NASDAQ: VTRS) | Delayed: 18.48 +0.03 (0.16%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.45 | 52 Week High | $ | |||
| Open | $18.45 | 52 Week Low | $ | |||
| Day High | $18.66 | P/E | N/A | |||
| Day Low | $18.35 | EPS | $ | |||
| Volume | 5,435,602 | |||||



